BRIEF-Erasca Inc - Reports Promising Early Clinical Data For ERAS-0015

Reuters01-12

Jan 12 (Reuters) - Erasca Inc ERAS.O:

ERASCA INC - REPORTS PROMISING EARLY CLINICAL DATA FOR ERAS-0015
ERASCA INC - PLANS PHASE 1 DATA RELEASE FOR ERAS-0015 AND ERAS-4001 IN 2026
ERASCA INC - REPORTS FAVORABLE SAFETY AND TOLERABILITY FOR ERAS-0015
ERASCA INC - PLANS PHASE 1 DATA FOR KRAS-MUTANT TUMORS IN H2 2026

Source text: ID:nGNX5QWp2L

Further company coverage: ERAS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602954858?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602954858","market":"fut","top_or_hot":-1,"title":"BRIEF-Erasca Inc - Reports Promising Early Clinical Data For ERAS-0015","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Erasca Inc - Reports Promising Early Clinical Data For ERAS-0015</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>Erasca Inc <span>ERAS.O</span>:</p><ul><li><p>ERASCA INC - REPORTS PROMISING EARLY CLINICAL DATA FOR ERAS-0015</p></li><li><p>ERASCA INC - PLANS PHASE 1 DATA RELEASE FOR ERAS-0015 AND ERAS-4001 IN 2026</p></li><li><p>ERASCA INC - REPORTS FAVORABLE SAFETY AND TOLERABILITY FOR ERAS-0015</p></li><li><p>ERASCA INC - PLANS PHASE 1 DATA FOR KRAS-MUTANT TUMORS IN H2 2026</p></li></ul><p>Source text: <span>ID:nGNX5QWp2L</span></p><p>Further company coverage: <span>ERAS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Erasca Inc - Reports Promising Early Clinical Data For ERAS-0015</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Erasca Inc - Reports Promising Early Clinical Data For ERAS-0015\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Erasca Inc - Reports Promising Early Clinical Data For ERAS-0015</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span>Erasca Inc <span>ERAS.O</span>:</p><ul><li><p>ERASCA INC - REPORTS PROMISING EARLY CLINICAL DATA FOR ERAS-0015</p></li><li><p>ERASCA INC - PLANS PHASE 1 DATA RELEASE FOR ERAS-0015 AND ERAS-4001 IN 2026</p></li><li><p>ERASCA INC - REPORTS FAVORABLE SAFETY AND TOLERABILITY FOR ERAS-0015</p></li><li><p>ERASCA INC - PLANS PHASE 1 DATA FOR KRAS-MUTANT TUMORS IN H2 2026</p></li></ul><p>Source text: <span>ID:nGNX5QWp2L</span></p><p>Further company coverage: <span>ERAS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ERAS","symbol_name":"Erasca, INC.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD16G:1","article_id":"2602954858","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602954858","pubTimestamp":1768224264,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Erasca Inc - Reports Promising Early Clinical Data For ERAS-0015Jan 12 (Reuters) - Erasca Inc ERAS.O:ERASCA INC - REPORTS PROMISING EARLY CLINICAL DATA FOR ERAS-0015ERASCA INC - PLANS PHASE 1 DA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ERAS":"Erasca, INC.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"简介-Erasca Inc-报告ERAS-0015有希望的早期临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":0.9},"content_text":"BRIEF-Erasca Inc - Reports Promising Early Clinical Data For ERAS-0015Jan 12 (Reuters) - Erasca Inc ERAS.O:ERASCA INC - REPORTS PROMISING EARLY CLINICAL DATA FOR ERAS-0015ERASCA INC - PLANS PHASE 1 DATA RELEASE FOR ERAS-0015 AND ERAS-4001 IN 2026ERASCA INC - REPORTS FAVORABLE SAFETY AND TOLERABILITY FOR ERAS-0015ERASCA INC - PLANS PHASE 1 DATA FOR KRAS-MUTANT TUMORS IN H2 2026Source text: ID:nGNX5QWp2LFurther company coverage: ERAS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602954858","isCrawlerRequest":true}